In our second interview, Dr. Leyfman shared his research on COVID-19 and cancer patients presented at the American Society of Clinical Oncology’s Annual Meeting or ASCO 2021. He discussed a radically different approach with an experimental cellular therapy, mesenchymal stem cells, which demonstrated a 91% overall survival and 100% survival in patients younger than 85 years old at one month after a single treatment. Please enjoy our video.
Here is the link to his ASCO abstract: Cancer and COVID-19: A Proposed Mechanism with Therapeutic Interventions
Here are some of the clinical trials using mesenchymal stem cells.
Here are the results of the trial that Dr. Leyfman references. The tabular format is not all that friendly.
Brian Koffman MDCM (retired) MS Ed (he, him, his)
Co-Founder, Executive VP, and Chief Medical Officer
CLL Society, Inc.
